Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 83.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
RR 1.42 [0.6, 3.33]
1 study · 129 participants
Very low

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found